Prototype Antimicrobial Blue Light Device Reduces MRSA in Porcine Wounds

Overview

A novel antimicrobial blue light (ABL) device significantly reduced methicillin-resistant Staphylococcus aureus (MRSA) infection by over 4 log units (>99.99%) in a preclinical swine wound model after just two daily treatments. This device offers a promising adjunct to antibiotics for managing infected skin wounds and potentially mitigating antimicrobial resistance.

Background

Cutaneous wound infections often involve biofilms that protect bacteria from antibiotics and delay healing, contributing to multidrug resistance. Antimicrobial blue light (ABL) at 405 nm has demonstrated bactericidal effects against various pathogens, including biofilms, by generating reactive oxygen species intracellularly. Despite promising in vitro and small animal data, no controlled studies have evaluated ABL in large animal models of significant wound infections prior to this investigation. MRSA was selected due to its prevalence and relative resistance to ABL, making it a rigorous test organism.

Data Highlights

Key Findings

• The ABL device delivered 405-nm light via a flexible, cooled PDMS dressing ensuring uniform illumination and stable skin temperature.
• In a porcine partial-thickness wound model heavily contaminated with MRSA, ABL treatment reduced bacterial burden by over 4 orders of magnitude compared to untreated controls.
• MRSA infections in this model exhibited biofilm characteristics, indicating the device’s efficacy against biofilm-associated bacteria.
• The device maintained skin temperature around 35°C, minimizing thermal injury risk during treatment.
• ABL’s mechanism involves excitation of endogenous bacterial chromophores producing reactive oxygen species, leading to bacterial cell death without inducing antibiotic resistance.
• No FDA- or EU-approved devices currently exist for treating significant cutaneous wound infections with ABL, highlighting the novelty of this prototype.

Clinical Implications

This ABL device could serve as an adjunct to antibiotic therapy in managing infected wounds, particularly those involving biofilms and multidrug-resistant organisms like MRSA. By reducing bacterial load rapidly, it may decrease antibiotic usage, treatment duration, and associated costs, contributing to antimicrobial stewardship. Further development and clinical trials are warranted to validate safety and efficacy in humans.

Conclusion

The prototype antimicrobial blue light device demonstrated potent bactericidal activity against MRSA in a clinically relevant porcine wound model, supporting its potential role in modern wound care to combat infection and antimicrobial resistance.

References

1. Abstract/Source/2024 -- A Prototype Antimicrobial Blue Light Device Effectively Manages Infected Wounds in a Preclinical Swine Model